vimarsana.com
Home
Live Updates
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis : vimarsana.com
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
MELBOURNE, Australia and NEW YORK, Jan. 24, 2024 -- Incannex Healthcare Inc. , , a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine...
Related Keywords
Australia
,
United States
,
Melbourne
,
Victoria
,
Joel Latham
,
Laine Yonker
,
Mark Bleackley
,
Incannex Healthcare Inc
,
Edison Group
,
Nasdaq
,
World Health Organisation
,
Globenewswire Inc
,
Hydroxychloroquine Sulphate
,
Patient Reported Outcomes
,
Scientific Officer
,
Magnetic Resonance Imaging
,
Health Organisation
,
Trial Assessing Tolerability
,
Securities Litigation Reform Act
,
Executive Officer
,
Relations Contact
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.